Five-Year Follow-up After Late Conversion From Calcineurin Inhibitors to Sirolimus in Patients With Chronic Renal Allograft Dysfunction

Transplantation Proceedings

Volumn 39, Issue 2, 2007, Pages 518-521

  Kruger B ^a   Fischereder, M ^b   Jauch, K W ^b   Graeb, C ^b   Hoffmann, U ^a   Boger C A ^a   Banas, B ^a   Obed, A ^c   Schlitt, H J ^c   Kramer B K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LOADING DRUG DOSE; MALE; NEPHROTOXICITY; PILOT STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

CALCINEURIN; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33847713330     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.12.004     Document Type: Article

References (9)

1. Racusen L.C., Solez K., and Colvin R. Fibrosis and atrophy in the renal allograft: interim report and new directions. Am J Transplant 2 (2002) 203
2. Pascual M., Theruvath T., Kawai T., et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 580
3. Fischereder M., Graeb C., Krüger B., et al. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 38 (2006) 1295
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 2 Suppl 1 (2002) S1
5. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6 (2006) 514
6. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22
7. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
8. Russ G., Segoloni G., Oberbauer R., et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 80 (2005) 1204
9. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869